At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 71 target
Drug / intervention
SHR-1701 Combined With Fluazopalildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SHR-1701 Combined With Fluzoparib as Maintenance Therapy for Advanced Lung Squamous Cell Carcinoma After Platium Based Chemo-immunotherapy
In Brief
A Phase 2 clinical trial evaluating SHR-1701 Combined With Fluazopalil for Non-Small Cell Lung Cancer. Targeting 71 participants across 1 site.
Detailed Summary
The purpose of the trial was to evaluate the efficacy and safety of SHR-1701 combined with fluzopar as a first-line treatment maintenance therapy for advanced lung squamous cell carcinoma. Patients with advanced or metastatic (stage IV) lung squamous cell carcinoma have not received systemic chemotherapy and have measurable lesions (RECIST 1.1) ECOG PS 0-1. The patient received SHR1701 +fluzoparib
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
20222023202420252026
First PostedJun 2021
Enrollment StartJul 2021
Primary CompletionDec 2024
Study CompletionJun 2025
TodayJul 2026
First PostedJun 24, 2021
Enrollment StartJul 1, 2021
Primary CompletionDec 1, 2024
Study CompletionJun 1, 2025
TodayJul 1, 2026
Enrollment to primary: 3.4 yearsPosted 5.0 years ago
Interventions
SHR-1701 Combined With Fluazopalildrug
SHR-1701 +fluzoparib